Alnylam Pharmaceuticals, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingNewest
None
No S-3 or F-3 shelf on file in the last 30 months.
None
No at-the-market programme on file in the last 30 months.
Warrants
The 10-Q filed 2026-07-30 is not read yet.
Cash
$3.31B
Operating cash flow was positive over the four quarters to 2026-06-30, so no quarters are counted. 10-Q ↗
Raised: 1 of its filings are not read yet.
Also on file: $1K convertible notes, 2025-09-12 8-K ↗